Heidi Anne Duerr

2 weeks ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REPORTERFor clinicians, researchers, and educators dedicated to improving outcomes in serious mental illness, the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting is more than just a professional gathering, it is a dynamic forum where innovation meets application, Joseph F. Goldberg, MD, told Psychiatric Times in an exclusive interview.

2 weeks ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REPORTERNew data presented at the 2025 American Psychiatric Association Annual Meeting demonstrated that zuranolone was relatively safe and effective to addressing anhedonia in adult patients with postpartum depression (PPD).

2 weeks ago | psychiatrictimes.com | Joe Feldman |Heidi Anne Duerr

CONFERENCE REPORTERA new nonprofit organization is supporting clinicians and patients in their fight for mental health coverage. In an interview with Psychiatric Times at the 2025 American Psychiatric Association Annual Meeting, Joe Feldman, president of Cover My Mental Health, referred to the current crisis in mental health and the frustrating and sometimes seemingly futile attempts to ensure appropriate evidence-based mental health care for patients is covered by insurance.

2 weeks ago | psychiatrictimes.com | Heidi Anne Duerr

CONFERENCE REEPORTER Researchers presented promising data for CPL’36, a phosphodiesterase 10A (PDE10A) inhibitor intended to treat acute schizophrenia exacerbation at the 2025 American Psychiatric Association (APA) Annual Meeting in Los Angeles, California.1 Jazwiec et al presented data from a double-blind, randomized, placebo controlled, parallel group phase 2 study (NCT05278156).2 The dose ranging study was designed to investigate the efficacy, safety, tolerability and pharmacokinetics...

3 weeks ago | psychiatrictimes.com | Amit Etkin |Heidi Anne Duerr

Alto Neuroscience is rapidly expanding its clinical pipeline with four ongoing phase 2 trials, all incorporating precision psychiatry approaches to target unmet needs in psychiatric treatment, Amit Etkin, MD, PhD, founder and CEO of Alto Neuroscience, told Psychiatric Times in a recent interview.